arrow
K

Keita Mori

Shizuoka Cancer Center
H指数:44
被引数:6,458

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase II Study of Cisplatin/Gemcitabine Plus Necitumumab for Squamous NSCLC After ICI-Platinum Therapy (WJOG14120L)

WJOG14120L研究:接受ICI-铂类方案治疗后鳞状非小细胞肺癌患者接受顺铂/吉西他滨联合尼昔妥木单抗治疗的II期研究

2026-10-010
OAAI
Efficacy of Osimertinib in Patients With Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations

奥希替尼对携带敏感EGFR突变且术后复发的非小细胞肺癌患者的疗效

2026-04-240
OAAI
Effect of the Insulated-Tip Knife on Procedure Time in Endoscopic Submucosal Dissection for Colorectal Neoplasms: A Single-Center, Randomized Controlled Trial (NANO Study)

绝缘尖端刀对结肠癌息肉内镜下黏膜下剥离术操作时间的影响:一项单中心、随机对照试验(NANO研究)

2025-10-210
PRE
ASO Visual Abstract: Functional Outcomes after Subtotal/Total Glossectomy with Microsurgical Reconstruction: a Multicenter Prospective Observational Study in Japan

ASO视觉摘要:部分/全舌切除术联合显微外科重建后的功能结局:一项在日本进行的多中心前瞻性观察研究

2025-09-030
PRE
Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing

II期研究:阿法替尼治疗携带罕见表皮生长因子受体突变(包括由下一代测序检测到的复合突变)的晚期非小细胞肺癌

2025-07-060
PRE
A randomized, double-blind, placebo-controlled phase III study evaluating the preventive effect of diclofenac cream on capecitabine-related hand-foot syndrome: study protocol of J-SUPPORT2401/JORTC-SUP06 (J-DIRECT)

一项随机、双盲、安慰剂对照的III期研究,评估双氯芬酸乳膏对卡培他滨相关手足综合征的预防效果:J-SUPPORT2401/JORTC-SUP06(J-DIRECT)研究方案

2025-05-140
OA
Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry

可手术的早期肺癌的质子和碳离子放射治疗; 前瞻性的全国注册

2024-09-010
PRE
A novel low-power pure-cut hot snare polypectomy for 10-14 mm colorectal adenomas: An ex vivo and a clinical prospective feasibility study (SHARP trial)
2023-12-272
PRE
Resectability of Small Duodenal Tumors: A Randomized Controlled Trial Comparing Underwater Endoscopic Mucosal Resection and Cold Snare Polypectomy
2023-12-225
PRE
Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)
2023-11-012
PRE
Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
2023-09-250
OAAI
Mitigation of paclitaxel-induced peripheral neuropathy in breast cancer patients using limb-cooling apparatus: a study protocol for a randomized controlled trial
2023-07-070
OAAI